Glucoraphanin (SGS): the stable sulforaphane precursor that finally gives a reliable dose

Sulforaphane has been one of the most intriguing molecules in nutritional pharmacology for two decades — a potent Nrf2 activator with cell-culture and animal evidence for cancer chemoprevention, anti-inflammatory effects, and metabolic improvements. Translating those signals into human trials has been frustrated by a basic chemistry problem: sulforaphane itself is unstable and degrades in supplements within months. The technology that has changed this is glucoraphanin (also called SGS — sulforaphane glucosinolate) paired with active myrosinase enzyme, which generates fresh sulforaphane in the gut at the time of consumption.

The stability problem and the solution

Sulforaphane is an isothiocyanate that hydrolyses, oxidises, and reacts with proteins on exposure to heat, moisture, or oxygen. Commercial sulforaphane supplements made from broccoli sprout powder typically lose 50–90% of their nominal sulforaphane content within 6 months of manufacture (PMID: 24732078).¹ Glucoraphanin is the stable glucosinolate precursor stored intact in broccoli sprouts. It is converted to sulforaphane by the enzyme myrosinase, which is also present in raw broccoli sprouts and in the human gut microbiome to a variable extent. Stabilised products containing glucoraphanin plus active myrosinase (Avmacol is the longest-studied) produce reliable sulforaphane release on contact with stomach acid and water.

What the human pharmacokinetic data show

A 2019 dose-finding study in 50 healthy adults found that 200 µmol glucoraphanin co-administered with active myrosinase produced peak plasma sulforaphane metabolite concentrations of 0.8–1.2 µM at 1–3 hours post-dose, with 24-hour urinary recovery of 45–55% of the administered dose (PMID: 31142067).² This bioavailability is approximately 4-fold higher than glucoraphanin alone (which relies on inconsistent microbiome-mediated conversion) and substantially more reproducible than preformed sulforaphane products which degrade unpredictably during storage.

The Johns Hopkins air pollution trial

The most influential SGS clinical trial was the 2014 Qidong China air pollution study, in which 291 adults living in a region with high airborne carcinogen exposure were randomised to a glucoraphanin-rich broccoli sprout beverage or placebo for 12 weeks (PMID: 24913818).³ The intervention produced 60% higher urinary excretion of mercapturic acid conjugates of benzene and 23% higher excretion of acrolein conjugates, indicating accelerated detoxification of two carcinogens of high public health relevance. The trial was not designed to detect cancer outcomes but established that the SGS-based intervention produced biomarker effects at the population scale.

The clinical signals that have followed

A 2024 trial in 65 adults with prediabetes randomised to SGS 150 µmol/day for 12 weeks reported a 0.3-percentage-point HbA1c reduction and a small but significant decrease in fasting glucose (PMID: 38625471).⁴ A 2022 trial in 40 children with autism spectrum disorder using SGS 100 µmol/day for 18 weeks showed modest improvement in behavioural assessment scores, though with high inter-subject variability (PMID: 36124589).⁵ Several SGS trials in non-alcoholic fatty liver disease have reported small reductions in ALT and steatosis on imaging, consistent with the Nrf2 hepatoprotective mechanism (PMID: 36879214).⁶ None of these trials has yet produced a definitive single-disease indication.

The cancer chemoprevention question

The Johns Hopkins program has pursued sulforaphane as a chemopreventive agent in head and neck cancer (Phase 2 trials in current oral cancer survivors), bladder cancer, and prostate cancer. A 2024 update from the program reported that SGS administration modulated cytokine and detoxification-enzyme expression in bladder mucosa at biopsy in a Phase 1b trial of 18 patients with non-muscle-invasive bladder cancer, supporting continuation to Phase 2 endpoint trials (PMID: 38542896).⁷ The cancer prevention case is mechanistically strong but remains in early human testing.

What this means for consumers

For an adult interested in sulforaphane supplementation, glucoraphanin paired with active myrosinase is the only product category with reproducible dosing. Doses in the 30–100 µmol range (commonly labelled 13–45 mg of glucoraphanin) have a reasonable safety record, deliver the published biomarker effects, and avoid the degradation problem that makes preformed sulforaphane products effectively unstandardisable. Fresh broccoli sprouts (3-day old, briefly chewed for myrosinase release) remain a credible and lower-cost alternative — roughly 60 g of fresh sprouts provides 50–80 µmol glucoraphanin — though convenience and consistency favour the standardised product for committed users. Buying "sulforaphane" without checking whether it is preformed (degrades) or glucoraphanin + myrosinase (stable) is the most common mistake in this category.